You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-CDKN1A (CDKN1A) Antibodies

Full name:
anti-Cyclin-Dependent Kinase Inhibitor 1A Antibodies (CDKN1A)
On www.antibodies-online.com are 4 Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) Antibodies from 2 different suppliers available. Additionally we are shipping CDKN1A Kits (8) and CDKN1A Proteins (3) and many more products for this protein. A total of 15 CDKN1A products are currently listed.
Synonyms:
CAP20, CDKI, Cdkn1, CIP1, MDA-6, mda6, P21, p21Cip1, p21WAF, SDI1, Waf1
list all antibodies Gene Name GeneID UniProt
CDKN1A 1026 P38936
Anti-Mouse CDKN1A CDKN1A 12575 P39689
CDKN1A    

Show all species

Show all synonyms

Most Popular Reactivities for anti-CDKN1A (CDKN1A) Antibodies

Select your species and application

anti-Human CDKN1A Antibodies:

anti-Rat (Rattus) CDKN1A Antibodies:

All available anti-CDKN1A Antibodies

Go to our pre-filtered search.

More Antibodies against CDKN1A Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) interaction partners

  1. LRRC8A (show LRRC8A Antibodies) is an essential regulator of cisplatin induced p53 (show TP53 Antibodies) protein activity and its downstream signaling involving increased expression of p21Waf1/Cip1 and MDM2 (show MDM2 Antibodies), as well as activation of caspase-9 (show CASP9 Antibodies) and -3 in tumor cell lines.

  2. USP28 (show USP28 Antibodies)-53BP1 (show TP53BP1 Antibodies)-p53 (show TP53 Antibodies)-p21 signaling pathway is also required to arrest cell growth after a prolonged prometaphase.

  3. A new study describes a long noncoding RNA, DINO, transcribed from the CDKN1A promoter region that induces stabilization of p53 (show TP53 Antibodies) protein and promotes efficient activation of p53 (show TP53 Antibodies) target genes in response to DNA damage.

  4. Cables1 (show CABLES1 Antibodies)/p21 pathway has a strong effect on the induction of cell senescence and inhibition of cell growth, and acts as a novel regulatory mechanism in which p21 is probably one of several downstream effector molecules to mediate Cables1 (show CABLES1 Antibodies).

  5. These results show that ASPL (show ASPSCR1 Antibodies)-TFE3 (show TFE3 Antibodies) regulates cell cycle progression and induces cellular senescence by up-regulating p21 expression.

  6. our study provides evidence that up-regulation of p21 is mainly responsible for the suppressive effect of miR (show MLXIP Antibodies)-1180-5p on human bladder cancer cells and miR (show MLXIP Antibodies)-1180-5p can significantly inhibit tumorigenicity in vivo.

  7. Low CIP1 expression is associated with renal cell carcinoma (show MOK Antibodies).

  8. RNA-binding motif 5 silencing reduced the messenger RNA and protein expression of the p53 (show TP53 Antibodies) target gene p21. Our results suggest that RNA-binding motif 5 downregulation is involved in gastric cancer progression and that RNA-binding motif 5 behaves as a tumor suppressor gene in gastric cancer

  9. These findings suggest that normal p53 (show TP53 Antibodies) function is crucial in ATM (show ATM Antibodies)/p53 (show TP53 Antibodies)/p21 pathway activated by LDIR. The p53 (show TP53 Antibodies) status is the most probable reason leading to differential LDIR biological activities between breast tumor cells and normal breast cells

  10. PPARg (show PPARG Antibodies) signaling pathway may involve in the proliferation inhibition of evodiamine on K562 cells via inhibiting cylcin D1 and stimulating of p21.

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 1A (CDKN1A) interaction partners

  1. telomerase activity and cardiomyocyte telomere length decrease sharply in wild-type mouse hearts after birth, resulting in cardiomyocytes with dysfunctional telomeres and anaphase bridges and positive for the cell-cycle arrest protein p21 (show D4S234E Antibodies).

  2. Consistent with the latter, Arid1a (show ARID1A Antibodies) reexpression in tumor cells led to increased p21 (Cdkn1a) expression and dramatic accumulation of cells in G2 phase of the cell cycle. These results also indicate a potential opportunity for therapeutic intervention in ARID1A (show ARID1A Antibodies)-deficient human breast cancer subtypes that retain one intact copy of the gene and also maintain wild-type TRP53 (show TP53 Antibodies) activity

  3. We discovered that FXR1P (show FXR1 Antibodies)-deficient aNSCs have altered expression of a select number of cell-cycle genes, and we identified the mRNA of cyclin-dependent kinase inhibitor 1A (Cdkn1a, p21 (show D4S234E Antibodies)) as a direct target of FXR1P (show FXR1 Antibodies).

  4. These results demonstrate that CQ and AQ increase the expression level of p21 (show D4S234E Antibodies) and inhibit T cell proliferation and the development of IFN-gamma (show IFNG Antibodies)-producing Th1 (show HAND1 Antibodies) cells, thereby revealing beneficial roles in treating a wide range of chronic inflammatory diseases mediated by inflammatory T cells.

  5. increases the number of ALP (show CCL21A Antibodies)-positive colonies after iPSC induction and decreases expression levels of Eomes (show EOMES Antibodies) and p21 (show D4S234E Antibodies) mRNAs. Based on these observations, we propose that the CCR4 (show CCR4 Antibodies)-NOT deadenylase activity contributes to iPSC induction.

  6. this study shows that p21 (show D4S234E Antibodies) is upregulated in T effector cells but not natural regulatory T cells after treatment with azacitidine, which protects from graft-versus-host Disease

  7. lincRNA-p21 (show D4S234E Antibodies) overexpression dramatically inhibited acetylation of H3 and H4 at the Thy-1 (show THY1 Antibodies) promoter and Thy-1 (show THY1 Antibodies) expression levels in HLF1 (show HLF Antibodies) cells. Finally, lincRNA-p21 (show D4S234E Antibodies) interference rescued LPS (show TLR4 Antibodies)-induced increase of lung and BAL collagen contents. LincRNA-p21 (show D4S234E Antibodies) could lead to pulmonary fibrosis in ARDS by inhibition of the expression of Thy-1 (show THY1 Antibodies).

  8. p21 (show D4S234E Antibodies) upregulation in hair follicle stem cells is associated with telogen retention in aged mice

  9. MiR-17-92 functions as a hepatocyte proliferation stimulator and acts in an estrogen-dependent manner. The loss of this miRNA results in increases in p21 (show D4S234E Antibodies) and Pten (show PTEN Antibodies) expression and therefore impairs liver regeneration in female mice.

  10. we observed that miR (show MLXIP Antibodies)-378 modulates the oscillation amplitudes of Cdkn1a in the control of cell cycle and Por (show POR Antibodies) in the regulation of oxidation reduction by forming partnership with different circadian transcription factors

CDKN1A Antigen Profile

Antigen Summary

This gene encodes a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Multiple alternatively spliced variants have been found for this gene.

Alternative names and synonyms associated with CDKN1A

  • cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) antibody
  • cyclin-dependent kinase inhibitor 1A (P21) (Cdkn1a) antibody
  • CAP20 antibody
  • CDKI antibody
  • Cdkn1 antibody
  • CIP1 antibody
  • MDA-6 antibody
  • mda6 antibody
  • P21 antibody
  • p21Cip1 antibody
  • p21WAF antibody
  • SDI1 antibody
  • Waf1 antibody

Protein level used designations for CDKN1A

CDK-interacting protein 1 , CDK-interaction protein 1 , DNA synthesis inhibitor , cyclin-dependent kinase inhibitor 1 , melanoma differentiation associated protein 6 , wild-type p53-activated fragment 1 , melanoma differentiation-associated protein , p21

GENE ID SPECIES
1026 Homo sapiens
12575 Mus musculus
Selected quality suppliers for anti-CDKN1A (CDKN1A) Antibodies
Did you look for something else?